Search results for "MAb"

B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)

2020

The B cell activating factor (BAFF), or B lymphocyte stimulator (BLyS), is a B cell survival factor which supports autoreactive B cells and prevents their deletion. BAFF expression is closely linked with autoimmunity and is enhanced by genetic alterations and viral infections. Furthermore, BAFF seems to be involved in adipogenesis, atherosclerosis, neuro-inflammatory processes and ischemia reperfusion (I/R) injury. BAFF is commonly overexpressed in Systemic Lupus Erythematosus (SLE) and strongly involved in the pathogenesis of the disease. The relationship between BAFF levels, disease activity and damage accrual in SLE is controversial, but growing evidence is emerging on its role in renal …

Lengthening the time intervals between doses of dupilumab in remission atopic dermatitis

2023

IL-9 IN PsA

2016

Objective. To investigate the expression and tis- sue distribution of Th9-related cytokines in patients with psoriatic arthritis (PsA). Methods. Quantitative gene expression analysis of Th1, Th17, and Th9 cytokines was performed in intestinal biopsy samples obtained from patients with PsA, HLA2B272positive patients with ankylosing spondylitis (AS), patients with Crohn’s disease (CD), and healthy controls. Expression and tissue distribu- tion of interleukin-23 (IL-23), IL-17, IL-22, IL-9, and IL-9 receptor (IL-9R) were evaluated by immunohisto- chemistry and confocal microscopy. Flow cytometry was used to study the frequency of Th9 cells among periph- eral blood, lamina propria, and synovial…

The Role of Inflammation in Lymphoma

2014

Human lymphomas usually develop in specialized tissue microenvironments characterized by different populations of accessory stromal and lymphoid cells that interact with malignant cells. A clinical role of the tumor microenvironment has recently emerged, bringing new knowledge and suggesting new ideas and targets for treatment. This chapter analyzes the microenvironment in human lymphomas highlighting the role of inflammation in their pathogenesis. Microenvironmental specificity is detailed according to different models including classic Hodgkin lymphoma (HL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma, unspecified and angioimmunoblastic T-ce…

Infliximab and emerging biological treatment for pediatric Crohn’s disease.

2009

Infliximab indispensabile per la remissione clinica nella malattia di Crohn refrattaria alla terapia tradizionale.

2005

1001 infusions of Infliximab in children with IBD: a 10 years study from the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition

2009

Teatralización en grupos tutorizados de Biología en Medicina: una estrategia diferente para el aprendizaje colaborativo.

2018

[EN] Dramatization as a teaching methodology remains relatively unknown in higher education. It can be especially useful to work cross-disciplinary skills because of the cooperative nature that is intrinsic to the theater itself. The subjects and disciplines that can benefit from it must be adequately valued by teachers. Here we present an activity in small groups, focused on rare diseases with a known genetic cause, in which the theater is used as a motivating axis to gather information and organize it by creating a storyline.

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or…

2008

Abstract Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized CD22 antibody, conjugated to calicheamicin, a potent cytotoxic antitumor agent. Inotuzumab ozogamicin targets B-cell malignancies since they often express CD22. In a previously reported phase 1 dose-escalation trial in patients with CD22-positive B-cell non-Hodgkin’s lymphoma (NHL), the maximum tolerated dose (MTD) was determined to be 1.8 mg/m2 every 4 weeks. Responses were seen in patients with both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). This ongoing study consisted of a limited dose escalation (DE) portion to confirm the MTD of inotuzumab ozogamicin whe…

Architectural improvements and FPGA implementation of a multimodel neuroprocessor

2003

Since neural networks (NNs) require an enormous amount of learning time, various kinds of dedicated parallel computers have been developed. In the paper a 2-D systolic array (SA) of dedicated processing elements (PEs) also called systolic cells (SCs) is presented as the heart of a multimodel neural-network accelerator. The instruction set of the SA allows the implementation of several neural algorithms, including error back propagation and a self organizing feature map algorithm. Several special architectural facilities are presented in the paper in order to improve the 2-D SA performance. A swapping mechanism of the weight matrix allows the implementation of NNs larger than 2-D SA. A systo…